

8226 Regency Drive, Pleasanton, CA 94588, USA

Telephone: +1-925-223-8242 Fax: +1-925-223-8243 E-mail: bpgoffice@wjgnet.com http://www.wjgnet.com

ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Gastroenterology

ESPS manuscript NO: 26115

Title: Management of hepatocellular carcinoma with portal vein tumor thrombosis:

Review and update at 2016 Reviewer's code: 02446404 Reviewer's country: Italy Science editor: Jing Yu

Date sent for review: 2016-04-01 17:20

Date reviewed: 2016-04-25 15:10

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
[] Grade A: Excellent	[Y] Grade A: Priority publishing	Google Search:	[Y] Accept
[Y] Grade B: Very good	[] Grade B: Minor language	[] The same title	[] High priority for
[] Grade C: Good	polishing	[] Duplicate publication	publication
[] Grade D: Fair	[] Grade C: A great deal of	[] Plagiarism	[] Rejection
[] Grade E: Poor	language polishing	[Y] No	[] Minor revision
	[] Grade D: Rejected	BPG Search:	[] Major revision
		[] The same title	
		[] Duplicate publication	
		[] Plagiarism	
		[Y]No	

COMMENTS TO AUTHORS

The paper by Chan et al. is a well written updated review according the evolving field of the therapeutic approaches to portal vein tumor trombosis in HCC patients. Due to the themes and accurateness the paper would be well situated for publication. Please include references for the following studies: 1) A PVTT confined to the hepatic lobe harboring the HCC (ipsilateral PVTT) is usually resected when a hepatectomy is conducted to remove the HCC (REF). 2) For the management of PVTT extending to the portal vein bifurcation or the main or contralateral portal vein, different approaches have been advocated. En-bloc resection including the bifurcation with or without the main portal vein and/or the contralateral portal vein is believed to produce good oncological outcomes (REF). 3) TACE is repeated every 8 to 12 weeks, and the treatment is to be stopped when there is progressive disease, extrahepatic disease, severe life-threatening complication, or evidence of liver failure or decompensation (serum total bilirubin >50umol/L, gross ascites uncontrollable with diuretics, or hepatic encephalopathy) (include references). The study by University of Hong Kong (ref 22) is randomized? Please specify



8226 Regency Drive, Pleasanton, CA 94588, USA Telephone: +1-925-223-8242 Fax: +1-925-223-8243

E-mail: bpgoffice@wjgnet.com http://www.wjgnet.com

ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Gastroenterology

ESPS manuscript NO: 26115

Title: Management of hepatocellular carcinoma with portal vein tumor thrombosis:

Review and update at 2016 Reviewer's code: 02860797 Reviewer's country: China Science editor: Jing Yu

Date sent for review: 2016-04-01 17:20

Date reviewed: 2016-05-08 11:54

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
[] Grade A: Excellent	[] Grade A: Priority publishing	Google Search:	[] Accept
[] Grade B: Very good	[Y] Grade B: Minor language	[] The same title	[] High priority for
[Y] Grade C: Good	polishing	[] Duplicate publication	publication
[] Grade D: Fair	[] Grade C: A great deal of	[] Plagiarism	[Y] Rejection
[] Grade E: Poor	language polishing	[Y]No	[] Minor revision
	[] Grade D: Rejected	BPG Search:	[] Major revision
		[] The same title	
		[] Duplicate publication	
		[] Plagiarism	
		[Y]No	

COMMENTS TO AUTHORS

1. This paper reviewed recent data on the management of HCC with PVTT, providing information for clinical practice, however it is similar with an recently published paper entitled 'Treatment of hepatocellular carcinoma with portal venous tumor thrombosis: A comprehensive review'. (WJG 2016). 2. The format of the tables should be unified.



8226 Regency Drive, Pleasanton, CA 94588, USA

Telephone: +1-925-223-8242 Fax: +1-925-223-8243 E-mail: bpgoffice@wjgnet.com http://www.wjgnet.com

ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Gastroenterology

ESPS manuscript NO: 26115

Title: Management of hepatocellular carcinoma with portal vein tumor thrombosis:

Review and update at 2016 Reviewer's code: 03538666 Reviewer's country: China Science editor: Jing Yu

Date sent for review: 2016-04-01 17:20

Date reviewed: 2016-05-20 06:40

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
[] Grade A: Excellent	[] Grade A: Priority publishing	Google Search:	[] Accept
[] Grade B: Very good	[Y] Grade B: Minor language	[] The same title	[Y] High priority for
[Y] Grade C: Good	polishing	[] Duplicate publication	publication
[] Grade D: Fair	[] Grade C: A great deal of	[] Plagiarism	[] Rejection
[] Grade E: Poor	language polishing	[Y] No	[] Minor revision
	[] Grade D: Rejected	BPG Search:	[] Major revision
		[] The same title	
		[] Duplicate publication	
		[] Plagiarism	
		[Y] No	

COMMENTS TO AUTHORS

However, there are several issues that should be addressed. 1. Grammatical error in Page 4 line 5: However, biopsy procedures are not frequently conducted in real-life situation for work-up of PVTT because of a small but potentially life-threatening complications including bleeding and injures to bile ducts or hepatic arteries [11]. 2. Typing error in Page 4 line 13: transartierial 3. Confusion expression in Page 7 line 9: The 3- and 5-year survival rates were 35.3% and 41.8% respectively in the Vp3 group and 21.2% and 20.9% respectively in the Vp4 group. 4. There are only OS data but DFS data in: Page 7 line 21: The 1-, 3- and 5-year overall survival rates were 50%, 12.5% and 12.5% respectively in Group 2 and 28.6%, 14.3% and 14.3% respectively in Group 3. Again, the two approaches had no significant difference in terms of overall survival and disease-free survival. 5. The interpretation for EACH study and the reason for adoption of FOLFOX are not so correct in Page 14 line 13: The overall study fails to demonstrate statistically significant difference between the two regimens but FOLFOX4 was found to have a small survival benefits in the subgroup population of Chinese patients [69, 70]. As a result, FOLFOX4 has been considered a standard treatment in China,



8226 Regency Drive, Pleasanton, CA 94588, USA Telephone: +1-925-223-8242 Fax: +1-925-223-8243 E-mail: bpgoffice@wjgnet.com http://www.wjgnet.com

where sorafenib is not widely available.



8226 Regency Drive, Pleasanton, CA 94588, USA Telephone: +1-925-223-8242 Fax: +1-925-223-8243

E-mail: bpgoffice@wjgnet.com http://www.wjgnet.com

ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Gastroenterology

ESPS manuscript NO: 26115

Title: Management of hepatocellular carcinoma with portal vein tumor thrombosis:

Review and update at 2016 Reviewer's code: 02944288 Reviewer's country: Russia Science editor: Jing Yu

Date sent for review: 2016-04-01 17:20

Date reviewed: 2016-05-20 09:53

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
[Y] Grade A: Excellent	[Y] Grade A: Priority publishing	Google Search:	[Y] Accept
[] Grade B: Very good	[] Grade B: Minor language	[] The same title	[] High priority for
[] Grade C: Good	polishing	[] Duplicate publication	publication
[] Grade D: Fair	[] Grade C: A great deal of	[] Plagiarism	[] Rejection
[] Grade E: Poor	language polishing	[Y] No	[] Minor revision
	[] Grade D: Rejected	BPG Search:	[] Major revision
		[] The same title	
		[] Duplicate publication	
		[] Plagiarism	
		[Y] No	

COMMENTS TO AUTHORS

Well done manuscript. Small note: when possible it's better to give the level of evidence for reviewed results and recommendations, though it's not critical.